|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01416311 |
|
Date of registration:
|
09/06/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Drug Use Investigation for REVOLADE (ITP)
|
|
Scientific title:
|
Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura) |
|
Date of first enrolment:
|
December 21, 2010 |
|
Target sample size:
|
5797 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01416311 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Contacts
|
|
Name:
|
Novartis Pharmaceuticals |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Novartis Pharmaceuticals |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subjects with chronic idiopathic thrombocytopenic purpura
Exclusion Criteria:
- Not applicable
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Purpura, Thrombocytopaenic, Idiopathic
|
|
Intervention(s)
|
|
Drug: Eltrombopag
|
|
Primary Outcome(s)
|
|
The number of subjects with any adverse events treated with REVOLADE
[Time Frame: 1 year]
|
|
Secondary Outcome(s)
|
|
Appearance of thromboembolism
[Time Frame: 1 year]
|
|
Secondary ID(s)
|
|
114877
|
|
CETB115B1401
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|